In the present study, two analyses were performed to investigate the hypotheses that: (1) prolonged exposure to anti-VEGF therapy is a risk factor for a reduction in outflow facility, and (2) patients with evidence for impaired outflow facility, in this case ocular hypertension, were more likely to experience a substantial reduction in outflow facility from anti-VEGF treatment. The gene discussed is VEGFA; the disease is ocular hypertension.